

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 28, 2022**

---

**ChemoCentryx, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35420**  
(Commission  
File Number)

**94-3254365**  
(IRS Employer  
Identification No.)

**835 Industrial Road, San Carlos, CA**  
(Address of Principal Executive Offices)

**94070**  
(Zip Code)

**Registrant's telephone number, including area code: (650) 210-2900**

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	CCXI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

## **Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

Effective as of June 28, 2022, the Board of Directors (the “Board”) of ChemoCentryx, Inc. (the “Company”) increased the size of the Board from eight to nine members, and upon the recommendation of the Nominating and Corporate Governance Committee and pursuant to the bylaws of the Company appointed Jennifer L. Herron, age 52, as an independent director. Ms. Herron was appointed to serve as a Class I director, with an initial term expiring at the 2024 annual meeting of stockholders of the Company.

Ms. Herron has served as Senior Vice President and Chief Commercial Officer of ADC Therapeutics since November 2019. Before joining ADC Therapeutics, Ms. Herron was Executive Vice President and Chief Commercial Officer at Immunogen from February 2019 to March 2019. She previously served as President and Executive Vice President, Global Commercial, at MorphoSys US from July 2018 to November 2018 and Executive Vice President and Chief Commercial Officer at Ariad Pharmaceuticals from May 2016 to April 2017. Earlier in her career, she held commercial leadership roles with Bristol-Myers Squibb, Novartis Oncology, and SmithKline Beecham Oncology (GlaxoSmithKline).

Ms. Herron holds an MBA from Georgetown University and a BA in Biology and Economics from Lehigh University.

There are no arrangements or understandings between Ms. Herron and any other persons pursuant to which she was selected as a director, and there are no related person transactions (within the meaning of Item 404(a) of Regulation S-K) between Ms. Herron and the Company.

## **Item 7.01. Regulation FD Disclosure**

On July 5, 2022, the Company issued a press release announcing changes to the composition of its Board of Directors. Jennifer L. Herron has been appointed to the Board as an independent director effective June 28, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this report.

The information contained in this Item 7.01, including the exhibit referenced herein, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

## **Item 9.01. Financial Statements and Exhibits**

### **(d) Exhibits**

The following exhibit is furnished herewith:

<u>Exhibit Number</u>	<u>Description</u>
99.1	<a href="#">Press release issued by ChemoCentryx, Inc., dated July 5, 2022.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMOCENTRYX, INC.

Date: July 5, 2022

By: /s/ Susan M. Kanaya

Name: Susan M. Kanaya

Title: Executive Vice President

Chief Financial and Administrative Officer and Secretary



### **ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director**

— Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board —

**SAN CARLOS, Calif., July 5, 2022** — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine.

“With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS® (avacopan) commercial efforts,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Jennifer’s values closely align with our organization, and we are confident this addition benefits patients, caregivers, and shareholders alike as we continue to grow and bring TAVNEOS to appropriate patients in need.”

Ms. Herron serves as Senior Vice President and Chief Commercial Officer of ADC Therapeutics, which she joined in November 2019 to build its commercial organization and launch its first marketed product. Before ADC Therapeutics, she was Executive Vice President and Chief Commercial Officer at Immunogen and President and Executive Vice President, Global Commercial, at MorphoSys US. In 2016 and 2017, Ms. Herron led the Commercial organization at Ariad Pharmaceuticals as Executive Vice President and Chief Commercial Officer and prepared the organization to launch its second commercial product. Earlier in her career, she held commercial leadership roles of increasing responsibility with Bristol-Myers Squibb, Novartis Oncology, and SmithKline Beecham Oncology (GlaxoSmithKline).

Ms. Herron holds an MBA from Georgetown University and a BA in Biology and Economics from Lehigh University.

“TAVNEOS is truly a unique medicine with potential to improve the lives of many patients that have been underserved for far too long,” said Ms. Herron. “I look forward to bringing my experience to ChemoCentryx, supplementing an already strong team with growing expertise in drug discovery, development, and commercial execution.”

#### **About ChemoCentryx**

ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In the United States, ChemoCentryx markets TAVNEOS® (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe hidradenitis suppurativa (HS) and C3 glomerulopathy (C3G).

ChemoCentryx is also developing CCX559, a highly potent orally administered small molecule PD-L1 checkpoint inhibitor, for the treatment of patients with solid tumors. A Phase I dose escalation study for CCX559 is ongoing and ChemoCentryx plans to advance to a Phase Ib/II study in the second half of 2022.

Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information about the Company visit [www.chemocentryx.com](http://www.chemocentryx.com).

TAVNEOS® is a registered trademark of ChemoCentryx, Inc. For more information, please see the [Full Prescribing Information](#) and [Medication Guide](#), available at [TAVNEOS.com](http://TAVNEOS.com).

### **Forward-Looking Statements**

ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company’s statements regarding the achievement of anticipated goals and milestones, whether the Company’s drug candidates will be shown to be safe and effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading “Risk Factors” in ChemoCentryx’s periodic reports filed with the SEC, including ChemoCentryx’s Annual Report on Form 10-K filed with the SEC on March 1, 2022, and its other reports which are available from the SEC’s website ([www.sec.gov](http://www.sec.gov)) and on ChemoCentryx’s website ([www.chemocentryx.com](http://www.chemocentryx.com)) under the heading “Investors.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

### **Contacts:**

#### **Investors:**

Bill Slattery, Jr.  
Vice President, Investor Relations  
& Corporate Communications  
650.210.2970  
[bslattery@chemocentryx.com](mailto:bslattery@chemocentryx.com)

#### **Media:**

Stephanie Tomei  
408.234.1279  
[media@chemocentryx.com](mailto:media@chemocentryx.com)